Drug class profile · refreshed daily from federal data

Platelet Aggregation Inhibitor

2 molecules in this class, $1.8M combined CY2024 Part D spend across 17K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Platelet Aggregation Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $1.8Mcombined across class
Total Rx claims: 17K5K unique beneficiaries
Generic mfrs (active): 16across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Dipyridamole

17K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 1996-10-18

8 generic mfrs 309 plans require PA

Low NADAC$0.216

→

Avg plan cost$0.267

Part D spend $1.8M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Eptifibatide

— Part D claims (CY24) · First FDA approval: 2015-12-08

8 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.